Improving the Delivery of Chronic Opioid Therapy Among People Living With Human Immunodeficiency Virus: A Cluster Randomized Clinical Trial.
HIV
chronic opioid therapy
chronic pain
pain management
prescription opioid misuse
Journal
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
ISSN: 1537-6591
Titre abrégé: Clin Infect Dis
Pays: United States
ID NLM: 9203213
Informations de publication
Date de publication:
05 10 2021
05 10 2021
Historique:
received:
06
03
2020
accepted:
16
07
2020
pubmed:
23
7
2020
medline:
21
10
2021
entrez:
23
7
2020
Statut:
ppublish
Résumé
Chronic pain is prevalent among people living with human immunodeficiency virus (PLWH); managing pain with chronic opioid therapy (COT) is common. Human immunodeficiency virus (HIV) providers often diverge from prescribing guidelines. This 2-arm, unblinded, cluster-randomized clinical trial assessed whether the Targeting Effective Analgesia in Clinics for HIV (TEACH) intervention improves guideline-concordant care compared to usual care for PLWH on COT. The trial was implemented from 2015 to 2018 with 12-month follow-up at safety-net hospital-based HIV clinics in Boston and Atlanta. We enrolled 41 providers and their 187 patients on COT. Prescribers were randomized 1:1 to either a 12-month intervention consisting of a nurse care manager with an interactive electronic registry, opioid education, academic detailing, and access to addiction specialists or a control condition consisting of usual care. Two primary outcomes were assessed through electronic medical records: ≥2 urine drug tests and any early COT refills by 12 months. Other outcomes included possible adverse consequences. At 12 months, the TEACH intervention arm had higher odds of ≥2 urine drug tests than the usual care arm (71% vs 20%; adjusted odds ratio [AOR], 13.38 [95% confidence interval {CI}, 5.85-30.60]; P < .0001). We did not detect a statistically significant difference in early refills (22% vs 30%; AOR, 0.55 [95% CI, .26-1.15]; P = .11), pain severity (6.30 vs 5.76; adjusted mean difference, 0.10 [95% CI, -1.56 to 1.75]; P = .91), or HIV viral load suppression (86.9% vs 82.1%; AOR, 1.21 [95% CI, .47-3.09]; P = .69). TEACH is a promising intervention to improve adherence to COT guidelines without evident adverse consequences.
Sections du résumé
BACKGROUND
Chronic pain is prevalent among people living with human immunodeficiency virus (PLWH); managing pain with chronic opioid therapy (COT) is common. Human immunodeficiency virus (HIV) providers often diverge from prescribing guidelines.
METHODS
This 2-arm, unblinded, cluster-randomized clinical trial assessed whether the Targeting Effective Analgesia in Clinics for HIV (TEACH) intervention improves guideline-concordant care compared to usual care for PLWH on COT. The trial was implemented from 2015 to 2018 with 12-month follow-up at safety-net hospital-based HIV clinics in Boston and Atlanta. We enrolled 41 providers and their 187 patients on COT. Prescribers were randomized 1:1 to either a 12-month intervention consisting of a nurse care manager with an interactive electronic registry, opioid education, academic detailing, and access to addiction specialists or a control condition consisting of usual care. Two primary outcomes were assessed through electronic medical records: ≥2 urine drug tests and any early COT refills by 12 months. Other outcomes included possible adverse consequences.
RESULTS
At 12 months, the TEACH intervention arm had higher odds of ≥2 urine drug tests than the usual care arm (71% vs 20%; adjusted odds ratio [AOR], 13.38 [95% confidence interval {CI}, 5.85-30.60]; P < .0001). We did not detect a statistically significant difference in early refills (22% vs 30%; AOR, 0.55 [95% CI, .26-1.15]; P = .11), pain severity (6.30 vs 5.76; adjusted mean difference, 0.10 [95% CI, -1.56 to 1.75]; P = .91), or HIV viral load suppression (86.9% vs 82.1%; AOR, 1.21 [95% CI, .47-3.09]; P = .69).
CONCLUSIONS
TEACH is a promising intervention to improve adherence to COT guidelines without evident adverse consequences.
Identifiants
pubmed: 32697847
pii: 5875079
doi: 10.1093/cid/ciaa1025
pmc: PMC8492355
doi:
Substances chimiques
Analgesics, Opioid
0
Types de publication
Journal Article
Randomized Controlled Trial
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
e2052-e2058Subventions
Organisme : NIAID NIH HHS
ID : P30 AI050409
Pays : United States
Organisme : NIDA NIH HHS
ID : R01 DA037768
Pays : United States
Organisme : NIAID NIH HHS
ID : P30 AI042853
Pays : United States
Organisme : NIAID NIH HHS
ID : P30 AI027757
Pays : United States
Informations de copyright
© The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.
Références
N Engl J Med. 2016 Sep 1;375(9):813-5
pubmed: 27579632
Pain Med. 2005 Nov-Dec;6(6):432-42
pubmed: 16336480
JAMA Intern Med. 2017 Sep 1;177(9):1265-1272
pubmed: 28715535
N Engl J Med. 2016 Jan 14;374(2):154-63
pubmed: 26760086
Annu Rev Med. 2018 Jan 29;69:451-465
pubmed: 29029586
Health Educ Behav. 2013 Oct;40(1 Suppl):74S-86S
pubmed: 24084403
JMIR Hum Factors. 2016 Jan 14;3(1):e2
pubmed: 27025985
J Pain Symptom Manage. 2012 Mar;43(3):638-45
pubmed: 22115794
Pain. 1997 Aug;72(1-2):235-43
pubmed: 9272808
JAMA. 2002 Oct 9;288(14):1775-9
pubmed: 12365965
Clin Infect Dis. 2019 Jan 7;68(2):291-297
pubmed: 29860411
Clin Infect Dis. 2017 Oct 30;65(10):e1-e37
pubmed: 29020263
JAMA. 2009 Mar 25;301(12):1242-52
pubmed: 19318652
J Nerv Ment Dis. 1980 Jan;168(1):26-33
pubmed: 7351540
Psychol Aging. 1997 Jun;12(2):277-87
pubmed: 9189988
HIV Res Clin Pract. 2019 Apr;20(2):48-63
pubmed: 31303143
Pain Med. 2007 Oct-Nov;8(7):573-84
pubmed: 17883742
J Acquir Immune Defic Syndr. 2011 Mar 1;56 Suppl 1:S91-7
pubmed: 21317601
AIDS Behav. 2019 Apr;23(4):1057-1061
pubmed: 30519904
J Pain. 2009 Feb;10(2):113-30
pubmed: 19187889
JAMA Intern Med. 2013 Feb 11;173(3):235-7
pubmed: 23319013
N Engl J Med. 2010 Dec 30;363(27):2611-20
pubmed: 21190455
Pain. 2016 Apr;157(4):931-937
pubmed: 26683238
JAMA. 2013 Sep 18;310(11):1156-67
pubmed: 24045740
MMWR Recomm Rep. 2016 Mar 18;65(1):1-49
pubmed: 26987082
Pain. 2011 Feb;152(2):397-402
pubmed: 21177035
Pain. 2007 Jul;130(1-2):144-56
pubmed: 17493754
J Acquir Immune Defic Syndr. 2018 Jul 1;78(3):283-290
pubmed: 29601405
JAMA Intern Med. 2017 Oct 1;177(10):1480-1488
pubmed: 28846769
J Pain. 2014 Nov;15(11):1130-1140
pubmed: 25152300
AIDS Care. 2019 Sep;31(9):1140-1144
pubmed: 30632790
Clin J Pain. 2004 Sep-Oct;20(5):309-18
pubmed: 15322437
BMJ. 1997 Jan 4;314(7073):23-8
pubmed: 9001475
Drug Alcohol Depend. 2017 Apr 1;173 Suppl 1:S1-S3
pubmed: 28363314
Arch Intern Med. 2011 Mar 14;171(5):425-31
pubmed: 21403039
Pain Med. 2012 Sep;13(9):1141-8
pubmed: 22846057